Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2020, 29(1):17-25

Cardiac amyloidosis - rare or underdiagnosed?

Danková M, Gonçalvesová E
Kardiologická klinika Lekárská Fakulty UK a Národný ústav srdcových a cievnych chorôb, a. s., Bratislava, Slovenská republika

Amyloidosis is a heterogenous disease consisting of the depositing of proteinous substance (amyloid) in body tissues. Cardiac amyloidosis is characterized by clinically significant extracellular amyloid infiltration of the heart by amyloid. Cardiac involvement represents the most important prognostic factor in AL amyloidosis and thus early diagnosis of amyloid heart disease is most important for further management. Recent clinical research has shown that amyloidosis, particularly TTR, is not so rare as it was thought. This review aims to discuss pathogenesis, manifestation, complex diagnostics and current therapeutic options of amyloidosis with the main focus on amyloid cardiomyopathy, documented in two case-reports.

Keywords: amyloidosis; amyloid cardiomyopathy; diagnostics; therapy

Published: January 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Danková M, Gonçalvesová E. Cardiac amyloidosis - rare or underdiagnosed? Cardiology Letters. 2020;29(1):17-25.
Download citation

References

  1. Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature and typing. Cardiovasc Pathol 2015;24:343-350. Go to original source...
  2. Donelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleveland Clinic Journal of Medicine 2017;84:suppl3. Go to original source...
  3. Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2019;25:1-5. Go to original source...
  4. Merlini G, Westermark MD. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 2004;255:159-178. Go to original source...
  5. Collins AB, Smith RN, Stone JR. Classification of amyloid deposits in diagnostic cardiac specimens by immunofluorescence. Cardiovasc Pathology 2008;18:205-216. Go to original source...
  6. Benson MD, Breall J, Cummings OW, et al. Biochemical characte­ risation of amyloid by endomyocardial biopsy. Amyloid 2009;16:9-14. Go to original source...
  7. Dubrey SW, Hawkins PN, Falk RH. Amyloid disease of the heart: assessment, diagnosis and referral. Heart 2011;97:75-84. Go to original source...
  8. Gertz MA, Comenzo R, Falk R, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005;79:319-328. Go to original source...
  9. Quock TP, Yan T, Chang E, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv 2018;2:1046-1053. Go to original source...
  10. Vermeer AMC, Janssen A, Boorsma PC, et al. Transthyretin amyloidosis: a phenocopy of hypertrophic cardiomyopathy. Amyloid 2017; 24:87-91. Go to original source...
  11. Cornwell GG III, Westermark P. Senile amyloidosis: a protein manifestation of the aging process. J Clin Pathol 1980;33:1146-1152. Go to original source...
  12. Gonzalez-Lopez E, Gallegoo-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:25852594. Go to original source...
  13. Longhi S, Lorenzini M, Gagliardi C, et al. Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2016;9:325-327. Go to original source...
  14. Mankad R, Grogan M. Diagnosis of cardiac amyloidosis: clinical and echocardiographic features. Curr Cardiovasc Imaging Rep 2018;11:32. Go to original source...
  15. Rapezzi S, Longhi S, Milandri A, et al. Cardiac involvement in hereditary-transthyretin related amyloidosis. Amyloid 2012;19:16-21. Go to original source...
  16. Maurer MS, Elliot P, Comenzo R, et al. Addressing commmon questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 2017;135:1357-1377. Go to original source...
  17. Bernardi L, Passino C, Porta C, et al. Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension? Heart 2008;88:615-621. Go to original source...
  18. Falk RH. Diagnosis and management of cardiac amyloidoses. Circulation 2005;112:2047-2060. Go to original source...
  19. Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 2007;116:2420-2426. Go to original source...
  20. Zubkov AY, Rabinstein AA, Dispenzieri A, et al. Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology 2007;69:1136-1141. Go to original source...
  21. Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 2000;109:181-188. Go to original source...
  22. Cyrille NB, Glodsmith J, Alvarez J, et al. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol 2014;114:1089-1093. Go to original source...
  23. Maurer MS, Elliott P, Comenzo R, et al. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 2017;135:1357-1377. Go to original source...
  24. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: an update on pathophysiology, diagnosis and treatment. Trends Cardiovasc Med 2018;28:10-21. Go to original source...
  25. Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and function in transthyretin-related versus lignt-chain cardiac amyloidosis. Circulation 2014;129:1840-1849. Go to original source...
  26. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010;3:155-164. Go to original source...
  27. Guy CD, Jones CK. Abdominal fat aspiration biopsy for tissue confirmation of systemic amyloidosis: specificity, positive predictive value and diagnostic pitfalls. Diagnostic Cytopathology 2001;24:181-185. Go to original source...
  28. Garcia Y, Collins AB, Stone JR. Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis. Hum Pathol 2018;72:71-79. Go to original source...
  29. Fine NM, Aruda-Olson AM, Dispenyieri A, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol 2014;113:1723-1727. Go to original source...
  30. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;13:24042412. Go to original source...
  31. Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis and treatment. Am J Hematol 2016;91:947-956. Go to original source...
  32. Emdin M, Aimo A, Rapezzi C, et al. Treatment of cardiac trans­ thyretin amyloidosis: an update. Eur Heart J 2019;0:1-10. Go to original source...
  33. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981;63:1285-1288. Go to original source...
  34. Gertz MA, Falk RH, Skinner M, et al. Worsening of congestive heart failure in amyloid heart disease treated by calcium channelblocking agents. Am J Cardiol 1985;55: 1645. Go to original source...